Patents Assigned to SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD.
  • Preparation of seimicarbazide-sensitive amine oxidase inhibitor and use thereof
    Patent number: 12258336
    Abstract: Provided are a preparation of semicarbazide-sensitive amine oxidase inhibitor and the use thereof. In particular, disclosed are a compound as shown in formula I, or a stereoisomer or racemate or pharmaceutically acceptable salt thereof. Also disclosed is that the above-mentioned compound can inhibit semicarbazide-sensitive amine oxidase.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: March 25, 2025
    Assignee: SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD.
    Inventors: Shengyang Liu, Jianwen Deng, Zhiyong Feng, Lei Jiang, Zhi Qiao, Ke Shang, Xiaoping Xie, Xueli Xu, Yuan Xu, Haixia Zhao
  • Aromatic heterocyclic compound with kinase inhibitory activity
    Patent number: 12234232
    Abstract: Provided are a JAK kinase inhibitor, preparation and use thereof. In particular, provided is a compound of Formula I, wherein each group is as described in the specification. The compound has an excellent JAK inhibitory activity, and therefore can be used to prepare pharmaceutical compositions for the treatment of cancer and other diseases related to JAK activity.
    Type: Grant
    Filed: September 23, 2019
    Date of Patent: February 25, 2025
    Assignee: SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD.
    Inventors: Lei Jiang, Jianwen Deng, Zhiyong Feng, Shengyang Liu, Xudong Mao, Ke Shang, Jianyong Shou, Danyi Wu, Xiaoping Xie, Yuan Xu, Haixia Zhao, Jianhua Zhang, Mingwei Zheng
  • Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof
    Patent number: 11787766
    Abstract: Provided are a compound for the prevention and treatment of diseases associated with PD-L1, a preparation method therefor and use thereof. Specifically, provided are the compound of formula I, the stereoisomer and the racemate thereof, or pharmaceutically acceptable salts thereof, and also provided is an application thereof in the preparation of a drug for the prevention and treatment of diseases associated with PD-L1.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: October 17, 2023
    Assignee: SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD.
    Inventors: Lei Jiang, Jianwen Deng, Xiaoli Lu, Ke Shang, Jianyong Shou, Bing Wang, Danyi Wu, Xueli Xu, Yuan Xu, Yi Zhang, Mingwei Zheng